文献速递结核与非结核分枝杆菌

美国结核病暴发调查的影响、成本与成本效果的模型分析

Model-Based Analysis of Impact, Costs, and Cost-effectiveness of Tuberculosis Outbreak Investigations, United States.
PubMed 文献 · Emerg Infect Dis · 2025-01-01

该研究模拟美国2023-2032年结核病暴发调查活动,估算其流行病学影响、经济成本(2022年美元)和增量成本效果比(每增加一个质量调整生命年的成本)。

要点

  • 暴发调查预计调查1,030,000名接触者,诊断4,130例结核病和104,000例潜伏结核感染。
  • 与无暴发调查相比,增量成本效果比为每质量调整生命年27,800美元。

核心结论

  • 暴发调查是美国结核病控制的重要组成部分,模型估计其具有流行病学影响和成本效果。

研究设计与样本

  • 模型分析,模拟美国2023-2032年结核病暴发调查活动,从医疗系统角度估算流行病学影响、经济成本(2022年美元)和增量成本效果比(每增加一个质量调整生命年的成本)。

主要发现

  • 预测暴发调查将调查1,030,000名接触者(95%不确定性区间376,000-1,740,000)。
  • 预测暴发调查导致4,130例结核病诊断(95%不确定性区间1,420-7,640)和104,000例潜伏结核感染诊断(95%不确定性区间37,600-181,000)。
  • 估计通过早期发现和治疗避免5,560例结核病(95%不确定性区间1,720-11,400)。

关键数值与推荐

  • 与无暴发调查相比,暴发调查的增量成本效果比为每获得一个质量调整生命年27,800美元(95%不确定性区间4,580-68,700美元)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outbreak investigation is an essential component of tuberculosis (TB) control in the United States, but its epidemiologic impact and cost-effectiveness have not been quantified. We modeled outbreak investigation activities in the United States during 2023-2032 and estimated corresponding epidemiologic impact, economic costs (in 2022 US$), and incremental cost-effectiveness ratios from the healthcare system perspective (cost per additional quality-adjusted life-year gained). We projected that outbreak investigations would result in 1,030,000 (95% uncertainty interval [UI] 376,000-1,740,000) contacts investigated, leading to 4,130 (95% UI 1,420-7,640) TB diagnoses and 104,000 (95% UI 37,600-181,000) latent TB infection diagnoses, at a total cost of US $219 million (95% UI $80-$387 million). We estimated that 5,560 (95% UI 1,720-11,400) TB cases would be averted through early detection and treatment, and the incremental cost-effectiveness of outbreak investigations, compared with no outbreak investigations, was $27,800 per quality-adjusted life-year gained (95% UI $4,580-$68,700).

来源:Emerg Infect Dis,查看原文。版权归原作者所有。

引用

  1. Shrestha S, Cilloni L, Asay GRB, et al. Model-Based Analysis of Impact, Costs, and Cost-effectiveness of Tuberculosis Outbreak Investigations, United States. Emerg Infect Dis. 2025. PMID: 40023804. doi:10.3201/eid3103.240633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。